secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2023-12-21T23:59:59+00:00
Accession:  0001193125-23-301206
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dianthus recasts audited financials for legacy OpCo; net loss $28.5M in 2022, going concern noted
--------------------------------------------------------------------------------

- Net loss of $28.5M in 2022, $13.1M in 2021; accumulated deficit $45.9M at Dec 31, 2022.
- Revenue from related party Zenas $6.4M in 2022, $1.5M in 2021; R&D expense $29.4M.
- Cash and investments $75.5M; going concern doubt due to insufficient capital for 12 months.
- Merger with Magenta closed Sep 11, 2023, accounted as reverse recapitalization; all historical shares restated at 0.2181 exchange ratio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000119312523301206/0001193125-23-301206-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000119312523301206/d639778d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-301206

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer